Spike proteins of SARS-CoV-2 relatives can evolve against immune responses
Scientists have shown that two species of seasonal human coronavirus related to SARS-CoV-2 can evolve in certain proteins to escape recognition by the immune system, according to a study published today in eLife.
The findings suggest that, if SARS-CoV-2 evolves in the same way, current vaccines against the virus may become outdated, requiring new ones to be made to match future strains.
When a person is infected by a virus or vaccinated against it, immune cells in their body will produce antibodies that can recognise and bind to unique proteins on the virus’ surface known as antigens. The immune system relies on being able to ‘remember’ the antigens that relate to a specific virus in order to provide immunity against it. However, in some viruses, such as the seasonal flu, those antigens are likely to change and evolve in a process called antigenic drift, meaning the immune system may no longer respond to reinfection.
“Some coronaviruses are known to reinfect humans but it is not clear to what extent this is due to our immune memory fading or antigenic drift,” says first author Kathryn Kistler, a PhD student at the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, US. “We wanted to investigate whether there is any evidence of coronaviruses related to SARS-CoV-2 evolving to evade our immune responses.”
The research team looked at the four seasonal human coronaviruses (HCoVs) which are related to SARS-CoV-2 but typically cause milder symptoms, such as the common cold. HCoVs have been circulating in the human population for 20-60 years, meaning their antigens would likely have faced pressure to evolve against our immune system.
The team used a variety of computational methods to compare the genetic sequences of many different strains of the viruses, enabling them to see how they have evolved over the years. They were especially interested in any changes that might have occurred in viral proteins that could contain antigens, such as spike proteins – the ray-like projections on the surface of coronaviruses that are particularly exposed to our immune system.
The researchers found a high rate of evolution in the spike proteins of two of the four viruses, OC43 and 229E. Nearly all of the beneficial mutations appeared in a specific region of the spike proteins called S1, which helps the virus infect human cells. This suggests that reinfection by these two viruses can occur as a result of antigenic drift as they evolve to escape recognition by the immune system.
The team also estimated that beneficial mutations in the spike proteins of OC43 and 229E appear roughly once every two to three years, about half to one-third of the rate seen in the flu virus strain, H3N2.
“Due to the high complexity and diversity of HCoVs, it is not entirely clear if this means that other coronaviruses, such as SARS-CoV-2, will evolve in the same way,” explains senior author Trevor Bedford, Principal Investigator and Associate Member at the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center. “The current vaccines against COVID-19, while highly effective, may need to be reformulated to match new strains, making it vital to continually monitor the evolution of the virus’ antigens.”
The paper ‘Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229E’ can be freely accessed online at https:/
Emily Packer, Media Relations Manager
Claire Hudson, Communications Manager
Fred Hutchinson Cancer Research Center
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Evolutionary Biology, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https:/
To read the latest Evolutionary Biology research published in eLife, visit https:/
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.